Humanetics

Humanetics Corporation to Present at Investor and Partnering Conferences

Retrieved on: 
Wednesday, February 7, 2024
Law Enforcement, Emergency Services, General Health, Public Policy, Government, Science, Military, Clinical Trials, Biotechnology, Health, Other Science, Research, Other Defense, Contracts, Defense, Radiology, Pharmaceutical, Homeland Security, Oncology, Humanetics, BIO, Biotechnology Innovation Organization, Conference, Growth, Pharmaceutical industry

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced that it will present and participate in several investor and partnering conferences in February.

Key Points: 
  • Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced that it will present and participate in several investor and partnering conferences in February.
  • The potential audience includes tens of thousands of individual and institutional investors, investment advisors, and analysts.
  • BIO CEO & Investor Conference, February 26-27, 2024, New York, NY
    Sponsored by the Biotechnology Industry Organization (BIO), the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded, late-stage private biotech companies.
  • Event registration: Register for the BIO CEO & Investor Conference .

Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, General Health, Pharmaceutical, Oncology, Health Technology, Veterans, Military, Other Defense, Defense, Contracts, Storm, Attention, American Public University System, MSN, Research, Humanetics, Radiation, RN, Certification, Kosovo Force, RET, Patient, BIO, BSN, COVID-19, University, DOD, Operation New Dawn, Knowledge, Army nursing, Nursing, Management

Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced the addition of Major General (Ret.)

Key Points: 
  • Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced the addition of Major General (Ret.)
  • Barbara R. Holcomb, RN, BSN, MSN to its board of directors.
  • “General Holcomb brings a wealth of knowledge and relevant experience that strengthens our Board,” said Ronald J. Zenk, Chief Executive Officer at Humanetics.
  • Humanetics is currently working under a contract with DOD to position BIO 300 for Emergency Use.

Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer

Retrieved on: 
Tuesday, November 14, 2023
Health, Pharmaceutical, Clinical, Research, Delta Omega, Navy, Medical corps, Joint Chiefs of Staff, Internal medicine, Patient, Emergency, American College, Gastroenterology, American College of Physicians, Chief of staff, Retirement, Peraton, Knowledge, Pharmaceutical industry, Management, Humanetics, Physician, Medicine, Defense

Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.

Key Points: 
  • Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.
  • Dr. Chinn, a distinguished medical professional and military leader, brings a wealth of knowledge and expertise to Humanetics Corporation.
  • In his new position as Chief Medical Officer at Humanetics Corporation, Dr. Chinn will guide the company's medical research and development efforts.
  • Dr. Chinn expressed his enthusiasm for his new role: “I am honored to join the exceptional team at Humanetics Corporation.

Keiretsu Forum’s Investor Capital Expo Highlights Resilience and Opportunity in Early-Stage Investments

Retrieved on: 
Monday, October 30, 2023
Humanetics, Health, Infection, Keiretsu Forum, Orion, Pediatrics, Kidney failure, Abuse, Weissmann, Gq alpha subunit, Research, Dialysis, Orthopedic surgery, Biotechnology, Angel Capital Association, Drug discovery, VC, Ligament, Tendon, Cancer, AI, Investment, Therapy, Defense, Patient, Automation, DART, Peritoneal dialysis, Fire, Capital, Tourism, Pharmaceutical industry, Q1

Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.

Key Points: 
  • Despite this backdrop, the 11th Annual Investor Capital Expo in Philadelphia on October 25, 2023, drew the participation of 200 forward-thinking accredited angel investors attending in person and virtually.
  • Keynote, Ron Weissman , Chair of the Angel Capital Association counselled participants that short-term demand for capital exceeds supply but, that this market correction is not a collapse.
  • Keiretsu Forum Mid-Atlantic and South-East is coming off of three consecutive years of record breaking angel member investments.
  • For more information on upcoming investor meetings and company presentations, contact Keiretsu Forum Mid-Atlantic and South-East at [email protected]

Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, October 24, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, Pulmonary fibrosis, Pneumonitis, NHLBI, Lung cancer, Small Business Innovation Research, SBIR, Idiopathic pulmonary fibrosis, National Heart, Lung, and Blood Institute, BIO, Inflammation, IPF, Quality of life, Radiation, Lung, Disease, Clinical trial, COVID-19, Therapy, Defense, Patient, Diagnosis, Injury, Bangladesh Technical Education Board, United States Department of Defense, Pharmaceutical industry, Humanetics

The funding will support a series of studies with its new drug candidate, BIO 300.

Key Points: 
  • The funding will support a series of studies with its new drug candidate, BIO 300.
  • The studies will focus on the ability of BIO 300 to attenuate progressive pulmonary fibrosis as a potential treatment for idiopathic pulmonary fibrosis (IPF).
  • Notably, the drug has been shown to mitigate inflammation of the lungs (pneumonitis) and pulmonary fibrosis caused by radiation.
  • Humanetics further expanded applications for the drug into cancer radiation therapy, COVID-19, and other inflammatory pulmonary diseases.

Premier Investment Showcase: The 11th Annual Investor Capital Expo in Philadelphia For The First Time Since 2019

Retrieved on: 
Tuesday, October 10, 2023
Capital, Keiretsu Forum, Investment, Infection, DART, Angel Capital Association, Humanetics, CST, Venture capital, Bacteria, Communication, Therapy, Kidney failure, Safety, Otitis, Fungus, GPCR, Cancer, G protein-coupled receptor, FDA, Cira Centre, Virus, Orthopedic surgery, Chairperson, Biotechnology, Mount Carmel East, Research, Mentorship, Financial services, Dentistry, Expo

Over 200 accredited angel investors from the Keiretsu Forum Mid-Atlantic and South-East are coming together for the 11th Annual Investor Capital Expo .

Key Points: 
  • Over 200 accredited angel investors from the Keiretsu Forum Mid-Atlantic and South-East are coming together for the 11th Annual Investor Capital Expo .
  • Twelve carefully screened early-stage entrepreneurs will pitch investors on October 25, 2023, at CYTO | Philly in the Cira Center.
  • Each presenting company is actively funding and has a complete Due Diligence Report and Investment Package.
  • The Investor Capital Expo provides a unique format for investors and breakthrough startups to learn, network, collaborate and forge relationships.

Avalution and Human Solutions become one within Humanetics

Retrieved on: 
Thursday, October 12, 2023
Software, Hardware, Automotive, Robotics, Data Management, Technology, Vehicle Technology, Other Technology, Multimedia, 3D, The Digital Group, Research, Industrial design, Humanetics

We are delighted to announce the combination of Avalution and Human Solutions into a single, seamlessly integrated entity, now operating within Humanetics’ Digital Group.

Key Points: 
  • We are delighted to announce the combination of Avalution and Human Solutions into a single, seamlessly integrated entity, now operating within Humanetics’ Digital Group.
  • These solutions, together with other digital and software solutions for safety engineering, remain the core foundation of Humanetics Digital.
  • Michael Stöhr, Managing Director of Avalution and Human Solutions, explained, “I am excited about the endless possibilities our full integration in Humanetics presents.
  • The Human Solutions and Avalution, teams, based in Kaiserslautern, Germany, are now registered as Humanetics Digital Europe.

Humanetics Unveils TrackBase Connect to Elevate Your Proving Ground Efficiency

Retrieved on: 
Thursday, September 28, 2023
Software, Hardware, Automotive, Robotics, Data Management, Technology, Vehicle Technology, Other Technology, Abstract, ISO, Multimedia, Crash, Humanetics, Advanced driver-assistance system, ADAS, UFO, Pedestrian, Safety, Online shopping, Mobile phone

Humanetics announced the launch of its new active safety proving grounds management tool, TrackBase Connect, to its customers gathered at the Humanetics Safety Summit in Germany.

Key Points: 
  • Humanetics announced the launch of its new active safety proving grounds management tool, TrackBase Connect, to its customers gathered at the Humanetics Safety Summit in Germany.
  • Following a successful first demonstration at the Digitrans proving ground in Linz, Austria, TrackBase Connect is now being rolled out to select customers in Europe, Asia and the U.S.
  • This synergy empowers our customers with a holistic approach to testing, boosting both efficiency and reliability.”
    To mark the launch of TrackBase Connect, Humanetics hosted an exclusive event at the Digitrans proving ground on September 12th.
  • Christoph Feichtinger of Digitrans stated, “TrackBase Connect by Humanetics has added revolutionary value to our Proving Ground.

Humanetics Corporation Publishes Positive Clinical Trial Results of BIO 300 in Patients with Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 19, 2023
Contracts, Law Enforcement, Emergency Services, Pharmaceutical, Oncology, General Health, Defense, Seniors, Public Policy, Government, Men, Clinical Trials, Family, Science, Consumer, Health, Research, Tidal volume, BIO, Radiation, COVID-19, Survival, Clinical trial, Cancer, Quality of life, Pharmacokinetics, Toxicity, Lung cancer, Radiation therapy, Pulmonary fibrosis, Humanetics, Patient, Canadian International Council, Risk, Neoplasm, Pulmonary toxicity, Chemoradiotherapy, Human, Safety, Medical imaging, Pharmaceutical industry, NSCLC

A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).

Key Points: 
  • A recently published paper in the International Journal of Radiation Oncology – Biology – Physics (Red Journal) details encouraging results from a multicenter clinical study conducted with Humanetics Corporation’s (Humanetics) novel radioprotective drug, BIO 300, in patients with non-small cell lung cancer (NSCLC).
  • Twenty-one patients were enrolled in the phase 1b/2a study evaluating the safety and clinical utility of BIO 300 as a radioprotector of normal tissues in patients with NSCLC ( NCT02567799 ).
  • In addition, patients receiving BIO 300 had a lower rate of hematological, pulmonary, and gastrointestinal toxicities compared to previous clinical studies with the same chemoradiotherapy regimen in the absence of BIO 300.
  • BIO 300 is also under advanced development as a radiation medical countermeasure for the military and first responders, and BIO 300 is in a phase 2b trial evaluating the clinical utility of BIO 300 to protect lung tissues against the long-term effects of COVID-19 ( NCT04482595 ).

Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

Retrieved on: 
Wednesday, September 6, 2023
Defense, Other Science, Radiology, White House, Federal Government, Pharmaceutical, Research, Other Defense, Oncology, Contracts, Homeland Security, Science, Clinical Trials, Public Policy, Government, FDA, Biotechnology, Health, Law Enforcement, Emergency Services, COVID-19, Military, BIO, Radiation, Acute radiation syndrome, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, United States Department of Defense, OTA, Policy, Clinical trial, Cancer, Lung cancer, Food and Drug Administration, Terrorism, Bangladesh Technical Education Board, DOD, JPM, Humanetics, Patient, Joint Program Executive Office Chemical and Biological Defense, Chronic radiation syndrome, Conventional weapon, Radiation exposure, Food, Pharmaceutical industry, Vaccine, Chemical substance

Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

Key Points: 
  • Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
  • In addition, the OTA agreement provides options for the DOD to fund all activities required to bring BIO 300 to full FDA approval.
  • Exposure to radiation from accidental or intentional sources can lead to acute radiation syndrome (ARS), which consists of numerous serious and life-threatening injuries.
  • The JPEO-CBRND will manage the OTA agreement, overseeing the development of BIO 300, exclusively licensed to Humanetics for advanced development and FDA licensing.